[go: up one dir, main page]

AR056991A1 - Derivados de urea, metodos para su fabricacion, y usos de los mismos - Google Patents

Derivados de urea, metodos para su fabricacion, y usos de los mismos

Info

Publication number
AR056991A1
AR056991A1 ARP060101666A ARP060101666A AR056991A1 AR 056991 A1 AR056991 A1 AR 056991A1 AR P060101666 A ARP060101666 A AR P060101666A AR P060101666 A ARP060101666 A AR P060101666A AR 056991 A1 AR056991 A1 AR 056991A1
Authority
AR
Argentina
Prior art keywords
groups
group
linear
same
different
Prior art date
Application number
ARP060101666A
Other languages
English (en)
Original Assignee
Proskelia S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proskelia S A S filed Critical Proskelia S A S
Publication of AR056991A1 publication Critical patent/AR056991A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Treating Waste Gases (AREA)

Abstract

Un proceso para su preparacion, su aplicacion por medio de medicamentos, y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1), donde: Y es oxígeno o azufre; R1 y R'1, son iguales o diferentes, y cada una representa un grupo arilo, un grupo heteroarilo, o R1 y R'1, junto con el átomo de carbono al cual están unidos, forman una estructura anular fusionada de formula (2), en la cual A representa un enlace simple, un grupo metileno, un grupo dimetileno, oxígeno, nitrogeno o azufre, estando dicho azufre opcionalmente en la forma de sulfoxido o sulfona; donde cada R1 y R'1, o dicha estructura anular fusionada formada de esta manera, está opcionalmente sustituida con al menos un sustituyente seleccionado del grupo c; donde el grupo c consiste en: átomos de halogeno, grupos hidroxilo, carboxilo, alquilo lineal o ramificado, hidroxialquilo; haloalquilo, alquiltio, alquenilo y alquinilo; grupos alcoxilo lineales y ramificados; grupos tioalquilo lineal y ramificados; hidroxicarbonilalquilo; alquilcarbonilo; alcoxicarbonilalquilo; carbonilo; trifluorometilo; trifluorometoxilo; -CN, -NO2; grupos alquilsulfonilo opcionalmente en las formas sulfoxido o sulfona; donde cualquier componente alquilo C1-6 y cualquiera alquenilo o alquinilo C2-6; y donde, cuando hay más de un sustituyente, entonces cada sustituyentes es igual o diferente; R2 y R'2, el cual puede ser el mismo o diferente, cada uno representa: un átomo de hidrogeno; un grupo alquilo lineal o ramificado C1-6 y opcionalmente está sustituido al menos con un átomo de halogeno, grupo hidroxi o alcoxi C1-6; un grupo alquilaminoalquilo o dialquilaminoalquilo donde cada grupo alquilo contiene C1-6; o R2 y R'2, junto con el átomo de nitrogeno al cual están unidos forman un heterociclo saturado o insaturado que contiene 0, 1 o 2 heteroátomos adicionales y que tienen 5, 6 o 7 átomos anulares, estando dicho grupo heterociclo opcionalmente sustituido por al menos un sustituyente seleccionado del grupo ôcö definido anteriormente; y donde, cuando hay más de un sustituyente, dicho sustituyente es igual o diferente; R3 representa un grupo de formula (3) o (4), en la cual B representa un átomo de oxígeno o un átomo de azufre, x es 0, 1 o 2, y e y' son iguales o diferentes, y cada uno es 0 o 1, Ar y Ar' son iguales o diferentes y cada uno representa un grupo arilo o heteroarilo, n y n' son iguales o diferentes y cada uno es 1, cuando el y o y' con el cual este se asocia es 0, o es igual al numero de posiciones que se pueden sustituir en el Ar o Ar' asociado cuando dicho y o y' es 1, el anillo fusionado que contiene Nx es un anillo heteroarilo de cinco o seis miembros, y donde R y R', que pueden ser iguales o diferentes, cada uno representa un átomo de hidrogeno o un sustituyente seleccionado del grupo a; donde el grupo a consiste en: átomos de halogeno, grupos hidroxilo; carboxilo; aldehído; alquilo lineal y ramificado, alquenilo, alquinilo, hidroxialquilo, hidroxialquenilo, hidroxialquinilo, haloalquilo, haloalquenilo, y haloalquinilo; grupos alcoxilo lineal o ramificados; grupos tioalquilo lineal o ramificados; grupos aralcoxi; grupos ariloxi; alcoxicarbonilo; aralcoxicarbonilo; ariloxicarbonilo; hidroxicarbonilalquilo; alcoxicarbonilalquilo; aralcoxicarbonilalquilo; ariloxicarbonilalquilo; perfluoroalquilo; perfluoroalcoxi; -CN; acilo; amino; alquilamino; aralquilamino; arilamino; dialquilamino; diaralquilamino; grupos diarilamino; acilamino y diacilamino; grupos alcoxicarbonilamino, aralcoxicarbonilamino, ariloxicarbonilamino, alquilcarbonilamino, aralquilcarbonilamino y arilcarbonilamino; grupos alquilaminocarboniloxi, aralquilaminocarboniloxi y arilaminocarboniloxi; grupos alquilo sustituidos con un amino, grupos alquilamino, aralquilamino, arilamino, dialquilamino, diaralquilamino, diarilamino, acilamino, trifluorometilcarbonil-amino, fluoroalquilcarbonilamino o diacilamino; CONH2; grupos alquil-aralquil- y arilamido; alquiltio, ariltio y aralquiltio y sus formas oxidadas sulfoxido y sulfona; grupos sulfonilo, alquilsulfonilo, haloalquilsulfonilo, arilsulfonilo y aralquilsulfonilo; sulfonamida, alquilsulfonamida, haloalquilsulfonamida, di(alquilsulfonil)amino, y grupos heterociclilo saturados e insaturados, siendo dichos grupos heterociclilo mono- o bi-cíclico y estando sustituidos opcionalmente con uno o más sustituyentes, que pueden ser iguales o diferentes, seleccionados del grupo b; donde el grupo b consiste en: átomos de halogeno, grupos hidroxilo; carboxilo; aldehído; alquilo lineal y ramificado, alquenilo, alquinilo, hidroxialquilo, grupos hidroxialquenilo, hidroxialquinilo, haloalquilo, haloalquenilo, y haloalquinilo; grupos alcoxilo lineal o ramificados; grupos tioalquilo lineal o ramificado; hidroxicarbonilalquilo; grupos alcoxicarbonilalquilo; perfluoroalquilo; perfluoroalcoxi; -CN; acilo; amino; alquilamino; dialquilamino; acilamino y diacilamino; grupos alquilo sustituidos con un grupo amino, alquilamino, dialquilamino, acilamino o diacilamino; CONH2; grupos alquilamido; alquiltio, y sus formas oxidadas sulfoxido y sulfona; grupos sulfonilo, alquilsulfonilo, y sulfonamida, alquilsulfonamida, y di(alquilsulfonil)amino; donde, en los grupos a y b, cualquiera de los componentes alquilo contiene C1-6, y cualquier componente alquenilo o alquinilo contiene C2-6, y está opcionalmente sustituido con al menos un átomo de halogeno o grupo hidroxi, y donde cualquier componente arilo está opcionalmente sustituido con un grupo heteroarilo; y sus sales y ésteres.
ARP060101666A 2005-04-29 2006-04-26 Derivados de urea, metodos para su fabricacion, y usos de los mismos AR056991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0504360A FR2885129B1 (fr) 2005-04-29 2005-04-29 Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.

Publications (1)

Publication Number Publication Date
AR056991A1 true AR056991A1 (es) 2007-11-07

Family

ID=35311522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101666A AR056991A1 (es) 2005-04-29 2006-04-26 Derivados de urea, metodos para su fabricacion, y usos de los mismos

Country Status (25)

Country Link
US (2) US8247412B2 (es)
EP (2) EP1874765B1 (es)
JP (1) JP4995189B2 (es)
KR (1) KR20080003380A (es)
CN (1) CN101238120A (es)
AR (1) AR056991A1 (es)
AT (1) ATE548368T1 (es)
AU (1) AU2006243328B2 (es)
BR (1) BRPI0611025A2 (es)
CA (1) CA2605008A1 (es)
CR (1) CR9469A (es)
CY (1) CY1112960T1 (es)
DK (1) DK1874765T3 (es)
EA (1) EA200702375A1 (es)
ES (1) ES2384052T3 (es)
FR (1) FR2885129B1 (es)
HR (1) HRP20120424T1 (es)
IL (1) IL186854A0 (es)
NO (1) NO20076145L (es)
PL (1) PL1874765T3 (es)
PT (1) PT1874765E (es)
TW (1) TW200714598A (es)
UY (1) UY29510A1 (es)
WO (1) WO2006117211A2 (es)
ZA (1) ZA200708871B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2007060026A1 (en) * 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
US8779004B2 (en) 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
AU2008233088B2 (en) 2007-03-30 2013-09-26 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
JP5321452B2 (ja) * 2007-05-08 2013-10-23 味の素株式会社 下痢の予防又は治療剤
US8324396B2 (en) * 2007-07-10 2012-12-04 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
US9725427B2 (en) 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
JP6700293B2 (ja) * 2015-03-03 2020-05-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． リルゾールプロドラッグおよびそれらの使用
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897242A (en) 1968-02-13 1975-07-29 Ciba Geigy Ag Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops
IL31574A0 (en) 1968-02-13 1969-04-30 Ciba Ltd Use of certain ureas for combating weeds
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
US4579947A (en) 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
US4521583A (en) 1984-02-09 1985-06-04 American Cyanamid Company Curable epoxy resin compositions
US4594373A (en) 1984-02-09 1986-06-10 American Cyanamid Company Curable epoxy resin compositions
FR2601363B1 (fr) * 1986-07-08 1988-10-21 Synthelabo (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique.
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DD298412A5 (de) 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
US5227397A (en) 1989-04-28 1993-07-13 Pfizer Inc. Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels
AU5957390A (en) 1989-07-03 1991-02-06 New York University Use of polyamines as ionic-channel regulating agents
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
ES2151618T3 (es) 1990-11-19 2001-01-01 Monsanto Co Inhibidores de proteasas retrovirales.
US5312928A (en) 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
ATE264292T1 (de) 1991-08-23 2004-04-15 Nps Pharma Inc Kalzium - receptor aktive arylalkylamine
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0641333B1 (en) 1992-05-20 1996-08-14 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
KR100187613B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테이제 억제 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
WO1996012697A2 (en) 1994-10-21 1996-05-02 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
WO1996014293A1 (fr) 1994-11-04 1996-05-17 Santen Pharmaceutical Co., Ltd. Nouveau derive de 1,3-dialkyluree ayant un groupe hydroxyle
DE69528197T2 (de) 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
JP3306571B2 (ja) 1995-06-28 2002-07-24 参天製薬株式会社 エンドセリン変換酵素阻害剤
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
US6022894A (en) 1996-04-09 2000-02-08 Nps Pharmaceuticals, Inc. Method of using calcilytic compounds
WO1999007672A1 (en) 1997-08-05 1999-02-18 Novo Nordisk A/S Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
EP0975589A2 (en) 1998-01-21 2000-02-02 ZymoGenetics, Inc. Dialkyl ureas as calcitonin mimetics
CN101481359A (zh) 1999-04-15 2009-07-15 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
US6365617B1 (en) * 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6598746B2 (en) * 2001-09-13 2003-07-29 Washburn Graphics, Inc. Display carton having an internally reinforced hanger panel
WO2004030669A1 (en) 2002-09-30 2004-04-15 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
JP2005336173A (ja) * 2004-04-27 2005-12-08 Santen Pharmaceut Co Ltd 骨粗鬆症治療剤
PT1757582E (pt) 2004-05-28 2016-03-04 Mitsubishi Tanabe Pharma Corp Arilalquilaminas e processo para a sua produção
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
PL1882684T3 (pl) 2005-05-19 2015-08-31 Astellas Pharma Inc Pochodna pirolidyny albo jej sól
WO2007060026A1 (en) 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
GB0613674D0 (en) 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
US8324396B2 (en) 2007-07-10 2012-12-04 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor

Also Published As

Publication number Publication date
WO2006117211A3 (en) 2007-01-11
EA200702375A1 (ru) 2008-06-30
HRP20120424T1 (hr) 2012-06-30
AU2006243328B2 (en) 2011-09-08
JP4995189B2 (ja) 2012-08-08
AU2006243328A1 (en) 2006-11-09
FR2885129A1 (fr) 2006-11-03
IL186854A0 (en) 2008-02-09
TW200714598A (en) 2007-04-16
BRPI0611025A2 (pt) 2016-11-16
CR9469A (es) 2008-03-06
US20100240889A1 (en) 2010-09-23
ES2384052T3 (es) 2012-06-28
ATE548368T1 (de) 2012-03-15
ZA200708871B (en) 2009-03-25
FR2885129B1 (fr) 2007-06-15
UY29510A1 (es) 2006-12-29
PL1874765T3 (pl) 2012-08-31
EP1874765A2 (en) 2008-01-09
DK1874765T3 (da) 2012-06-18
US20120283255A1 (en) 2012-11-08
PT1874765E (pt) 2012-05-25
CY1112960T1 (el) 2016-04-13
CA2605008A1 (en) 2006-11-09
JP2008539186A (ja) 2008-11-13
CN101238120A (zh) 2008-08-06
EP2354137A1 (en) 2011-08-10
WO2006117211A2 (en) 2006-11-09
EP1874765B1 (en) 2012-03-07
NO20076145L (no) 2008-01-28
US8247412B2 (en) 2012-08-21
KR20080003380A (ko) 2008-01-07

Similar Documents

Publication Publication Date Title
AR056991A1 (es) Derivados de urea, metodos para su fabricacion, y usos de los mismos
PE20230162A1 (es) Derivados espirancos sustituidos de cadena lineal
AR058095A1 (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas. procesos de obtencion y composiciones farmaceuticas.
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR055620A1 (es) Derivados de cicloalcano-carboxamidas
AR056686A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
AR058006A1 (es) Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos
GT200600164A (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
AR070925A1 (es) 4- hidroxipirimidina -5- carboxamida sustituidas, un procedimiento para el tratamiento preventivo de anemia, procedimiento para potenciar la produccion endogena de eritropoyetina, uso del compuesto en la fabricacion de un medicamento y composicion farmaceutica
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
AR038172A1 (es) Compuesto de ciclohexano y ciclohexeno, su uso para preparar una composicion farmaceutica, dicha composicion farmaceutica, procedimiento para preparar el compuesto y compuestos intermediarios en dicho procedimiento
AR064454A1 (es) Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR056864A1 (es) Derivados de (heteroariloxibencil)benceno sustituidos con glucopiranosilo, medicamentos que contienen estos compuestos, su uso y procedimiento para su fabricacion
AR061583A1 (es) Acidos 6-(bencilo sustituido con heterociclil)-4-oxiquinolin carboxilicos, inhibidores de vih-integrasas, composiciones farmaceuticas que los contienen y usos como agentes anti-vih.
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR035858A1 (es) Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3

Legal Events

Date Code Title Description
FB Suspension of granting procedure